12 Lung Cancer Clinical Trials in Daphne, AL (2026)

Q: How do I join a clinical trial in Daphne?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Daphne research site will contact you.

Recruiting Lung Cancer Studies in Daphne

NCT03851445Recruiting

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to ...

Daphne, ALPHASE210,000 participantsSWOG Cancer Research Network

View Study Details

NCT07361497Recruiting

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

A study to evaluate Pumitamig versus Durvalumab following concurrent chemoradiation therapy in participants with unresectable stage III Non-small Cell Lung Cancer (NSCLC)...

Daphne, ALPHASE3850 participantsBristol-Myers Squibb

View Study Details

NCT07365319Recruiting

A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

This is a study to evaluate the safety and efficacy of EIK1001 administered intravenously in combination with pembrolizumab and histologically appropriate chemotherapy for patients with stage 4 NSCLC....

Daphne, ALPHASE2750 participantsEikon Therapeutics

View Study Details

NCT07361510Recruiting

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

The purpose of this study is to evaluate the efficacy of Pumitamig versus Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%....

Daphne, ALPHASE3750 participantsBristol-Myers Squibb

View Study Details

NCT06646276Recruiting

A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

The Purpose of the Study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide to that of Atezolizumab...

Daphne, ALPHASE3530 participantsBristol-Myers Squibb

View Study Details

NCT06667076Recruiting

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

The primary purpose of the study is to assess how well amivantamab in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth f...

Daphne, ALPHASE2480 participantsJanssen Research & Development, LLC

View Study Details

NCT05624996Recruiting

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer

This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by ...

Daphne, ALPHASE3474 participantsNRG Oncology

View Study Details

NCT06616584Recruiting

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

This phase II/III Expanded Lung-MAP treatment trial compares the effect of adding cemiplimab to docetaxel and ramucirumab versus docetaxel and ramucirumab alone in treating patients with non-small cel...

Daphne, ALPHASE2378 participantsSWOG Cancer Research Network

View Study Details

NCT06773910Recruiting

BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)

This is an open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab in limited-stage (LS)-small-cell lung cancer (SCLC) participants. The main goals of...

Daphne, ALPHASE2250 participantsSCRI Development Innovations, LLC

View Study Details

NCT06095505Recruiting

A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer

PUMA-ALI-4201 is a Phase 2 study evaluating alisertib monotherapy in patients with pathologically-confirmed small cell lung cancer (SCLC) following progression on or after treatment with one platinum-...

Daphne, ALPHASE2120 participantsPuma Biotechnology, Inc.

View Study Details

NCT05642572Recruiting

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small cell lung cancer that may have spread fr...

Daphne, ALPHASE266 participantsSWOG Cancer Research Network

View Study Details

NCT06031688Recruiting

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first s...

Daphne, ALPHASE256 participantsSWOG Cancer Research Network

View Study Details

About Lung Cancer Clinical Trials in Daphne

Lung cancer is the leading cause of cancer death worldwide, starting in the cells of the lungs. The two main types are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Treatments include surgery, chemotherapy, radiation, immunotherapy, and targeted drugs.

There are currently 12 lung cancer clinical trials recruiting participants in Daphne, AL. These studies are seeking a combined 14,704 participants. Research is being sponsored by SWOG Cancer Research Network, Bristol-Myers Squibb, Eikon Therapeutics and 4 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Lung Cancer Clinical Trials in Daphne — FAQ

Are there lung cancer clinical trials in Daphne?

Yes, there are 12 lung cancer clinical trials currently recruiting in Daphne, AL. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Daphne?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Daphne research site will contact you about next steps.

Are clinical trials in Daphne free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Daphne studies also compensate for your time and travel.

What lung cancer treatments are being tested?

The 12 active trials in Daphne are testing new therapies including novel drugs, biologics, and treatment approaches for lung cancer.

Data updated July 22, 2026 from ClinicalTrials.gov